Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 75 of 741 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/07/20
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 01/01/23
End: 12/31/39
Due: 12/31/40
Phase: N/A
Priority: Normal
Start: 08/01/19
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 03/01/22
End: 09/01/22
Due: 09/01/23
Phase: N/A
Priority: Normal
Start: 12/09/22
End: 02/02/31
Due: 02/02/32
Phase: N/A
Priority: Normal
Start: 05/01/21
End: 12/30/24
Due: 12/30/25
Phase: N/A
Priority: Normal
Start: 08/30/24
End: 08/30/26
Due: 08/30/27
Phase: N/A
Priority: Normal
Start: 07/06/23
End: 05/31/26
Due: 05/31/27
Phase: N/A
Priority: Normal
Start: 06/14/22
End: 12/24/23
Due: 12/24/24
Phase: N/A
Priority: Normal
Start: 03/01/24
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 11/25/21
End: 12/25/24
Due: 12/25/25
Phase: N/A
Priority: Normal
Start: 03/05/24
End: 12/30/28
Due: 12/30/29
Phase: N/A
Priority: Normal
Start: 03/31/23
End: 03/31/23
Due: 03/31/24
Phase: N/A
Priority: Normal
Start: 10/01/19
End: 08/01/27
Due: 08/01/28
Phase: N/A
Priority: Normal
Start: 09/15/23
End: 05/31/25
Due: 05/31/26
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Phase: N/A
Priority: Normal
Start: 02/01/23
End: 02/01/26
Due: 02/01/27
Phase: N/A
Priority: Normal
Start: 06/01/18
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 10/14/20
End: 09/01/24
Due: 09/01/25
Phase: N/A
Priority: Normal
Start: 01/22/20
End: 01/27/21
Due: 01/27/22
Phase: N/A
Priority: Normal
Start: 12/01/18
End: 07/31/19
Due: 07/31/20
Phase: N/A
Priority: Normal
Start: 02/01/23
End: 03/01/25
Due: 03/01/26
Phase: N/A
Priority: Normal
Start: 01/16/25
End: 01/01/28
Due: 01/01/29
Phase: N/A
Priority: Normal
Start: 10/12/23
End: 10/30/28
Due: 10/30/29
Phase: N/A
Priority: Normal
Start: 06/20/22
End: 12/31/27
Due: 12/31/28